Brazikumab
Pharmaceutical drug
From Wikipedia, the free encyclopedia
Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2] It targets IL-23.[3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL23 |
| Clinical data | |
| Other names | MEDI2070 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6410H9830N1718O2016S50 |
| Molar mass | 144820.16 g·mol−1 |
This drug was developed by MedImmune, LLC.
